Not all cancer therapies are successful, but cancer researchers increasingly are able to identify the right treatments for the right patients at the right time. A researcher at the University of Oklahoma has helped lead a ...
Mar 21, 2024
0
30
Colorectal cancer (CRC) presents with varying clinical characteristics due to tumor heterogeneity. Microsatellite instability (MSI), present in 10–15% of CRC cases, indicates a different clinical trajectory than microsatellite ...
Dec 15, 2023
0
0
In a study published today in Nature Communications, a team of scientists from French-American techbio Owkin and pathology labs in France present a blind validation of MSIntuit CRC, a first-in-class AI-driven digital pathology ...
Nov 7, 2023
0
3
Genomic profiling of patients who were treated for colorectal cancer at a major U.S. cancer center showed that patients with African ancestry had fewer actionable mutations than patients with European ancestry and were less ...
Apr 17, 2023
0
3
The immense progress in the field of therapy options over the past years has significantly improved the chances of cure for patients with colon cancer. However, these new approaches, such as immunotherapies, require precise ...
Feb 14, 2023
0
41
A team of researchers with member affiliations across the U.S. and Canada has found evidence of multiple recurrent, repeat expansions in human cancer genomes. In their paper published in the journal Nature, the group describes ...
Results of a study led by VHIO investigators and published in Nature Medicine have unmasked mutations in the RNF43 gene as predictive biomarkers of response to treatment with anti-BRAF/EGFR combinatory therapy in patients ...
Sep 27, 2022
0
35
Researchers have developed a new integrated genetic/epigenetic DNA-sequencing protocol known as MultiMMR that can identify the presence and cause of mismatch repair (MMR) deficiency in a single test from a small sample of ...
Jan 21, 2021
0
5
A large international trial involving UCL and University College London Hospitals NHS Foundation Trust (UCLH) has found that pembrolizumab, a form of immunotherapy, more than doubled the 'progression free survival' time of ...
May 29, 2020
0
3
A study at The University of Texas MD Anderson Cancer Center discovered a novel therapeutic vulnerability for patients who have tumors caused by a genetic misfire in the DNA mismatch repair (MMR) pathway, a system for repairing ...
Feb 27, 2020
0
2
